{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:03:39Z","timestamp":1793361819296,"version":"4.5.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002997","name":"Nierstichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The rare and heterogeneous kidney disorder C3 glomerulopathy (C3G) is characterized by dysregulation of the alternative pathway (AP) of the complement system. C3G is often associated with autoantibodies stabilizing the AP C3 convertase named C3 nephritic factors (C3NeF). The role of classical pathway (CP) convertase stabilization in C3G and related diseases such as immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) remains largely unknown. Here, we investigated the CP convertase activity in patients with C3G and IC-MPGN. Using a refined two-step hemolytic assay, we measured the stability of CP convertases directly in the serum of 52 patients and 17 healthy controls. In four patients, CP convertase activity was prolonged compared to healthy controls, i.e. the enzymatic complex was stabilized. In three patients (2 C3G, 1 IC-MPGN) the convertase stabilization was caused by immunoglobulins, indicating the presence of autoantibodies named C4 nephritic factors (C4NeFs). Importantly, the assay also enabled detection of non-immunoglobulin-mediated stabilization of the CP convertase in one patient with C3G. Prolonged CP convertase activity coincided with C3NeF activity in all patients and for up to 70 months of observation. Crucially, experiments with C3-depleted serum showed that C4NeFs stabilized the CP C3 convertase (C4bC2a), that does not contain C3NeF epitopes. All patients with prolonged CP convertase activity showed clear signs of complement activation, i.e. lowered C3 and C5 levels and elevated levels of C3d, C3bc, C3bBbP, and C5b-9. In conclusion, this work provides new insights into the diverse aspects and (non-)immunoglobulin nature of factors causing CP convertase overactivity in C3G\/IC-MPGN.<\/jats:p>","DOI":"10.3389\/fimmu.2021.715704","type":"journal-article","created":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T09:06:10Z","timestamp":1628672770000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis"],"prefix":"10.3389","volume":"12","author":[{"given":"Marloes A. H. M.","family":"Michels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C. A. J.","family":"van de Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne A. W.","family":"van Kraaij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian A.","family":"Sarlea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Gracchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flore A. P. T.","family":"Engels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiske M.","family":"Dorresteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"van der Deure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Duineveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack F. M.","family":"Wetzels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambertus P. W. J.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena B.","family":"Volokhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.377","article-title":"C3 Glomerulopathy: Consensus Report","volume":"84","author":"Pickering","year":"2013","journal-title":"Kidney Int"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 Glomerulopathy - Understanding a Rare Complement-Driven Renal Disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy: Conclusions From a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2010.85","article-title":"C3 Glomerulopathy: A New Classification","volume":"6","author":"Fakhouri","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and Genetic Complement Abnormalities Play a Critical Role in Dense Deposit Disease and Other C3 Glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.212","article-title":"C3 Glomerulonephritis: Clinicopathological Findings, Complement Abnormalities, Glomerular Proteomic Profile, Treatment, and Follow-Up","volume":"82","author":"Sethi","year":"2012","journal-title":"Kidney Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07900811","article-title":"Causes of Alternative Pathway Dysregulation in Dense Deposit Disease","volume":"7","author":"Zhang","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2016.01.010","article-title":"Complement Gene Variants Determine the Risk of Immunoglobulin-Associated MPGN and C3 Glomerulopathy and Predict Long-Term Renal Outcome","volume":"71","author":"Iatropoulos","year":"2016","journal-title":"Mol Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019040433","article-title":"Large-Scale Whole-Genome Sequencing Reveals the Genetic Architecture of Primary Membranoproliferative GN and C3 Glomerulopathy","volume":"31","author":"Levine","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfz073","article-title":"Validation of Distinct Pathogenic Patterns in a Cohort of Membranoproliferative Glomerulonephritis Patients by Cluster Analysis","volume":"13","author":"Garam","year":"2020","journal-title":"Clin Kidney J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017030258","article-title":"Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies\/Immune Complex-Mediated Membranoproliferative Gn","volume":"29","author":"Iatropoulos","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2008.00350.x","article-title":"The Alternative Complement Pathway Revisited","volume":"12","author":"Harboe","year":"2008","journal-title":"J Cell Mol Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement System Part I - Molecular Mechanisms of Activation and Regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1923","article-title":"Complement: A Key System for Immune Surveillance and Homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12388","article-title":"A Novel Method for Direct Measurement of Complement Convertases Activity in Human Serum","volume":"178","author":"Blom","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s13023-019-1237-8","article-title":"C4 Nephritic Factor in Patients With Immune-Complex-Mediated Membranoproliferative Glomerulonephritis and C3-Glomerulopathy","volume":"14","author":"Garam","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.07.004","article-title":"C4 Nephritic Factors in C3 Glomerulopathy: A Case Series","volume":"70","author":"Zhang","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.138.401","article-title":"Nephritic Factor (NeF) of Alternate Pathway (NeFA) and of Classical Pathway (NeFc)","volume":"138","author":"Arakawa","year":"1982","journal-title":"Tohoku J Exp Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1994.tb06530.x","article-title":"Occurrence of C3 Nephritic Factor and C4 Nephritic Factor in Membranoproliferative Glomerulonephritis (MPGN)","volume":"95","author":"Ohi","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"B20","article-title":"C3 Nephritic Factor and C4 Nephritic Factor in the Serum of Two Patients With Hypocomplementaemic Membranoproliferative Glomerulonephritis","volume":"76","author":"Tanuma","year":"1989","journal-title":"Clin Exp Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI109787","article-title":"Nephritic Factor of the Classical Pathway of Complement: Immunoglobulin G Autoantibody Directed Against the Classical Pathway C3 Convetase Enzyme","volume":"65","author":"Halbwachs","year":"1980","journal-title":"J Clin Invest"},{"key":"B22","article-title":"Heterogeneity, Polypeptide Chain Composition and Antigenic Reactivity of Autoantibodies (F-42) That Are Directed Against the Classical Pathway C3 Convertase of Complement and Isolated From Sera of Patients With Systemic Lupus Erythematosus","volume":"56","author":"Daha","year":"1984","journal-title":"Clin Exp Immunol"},{"key":"B23","article-title":"Stabilization of the Classical Pathway C3 Convertase C42, by a Factor F-42, Isolated From Serum of Patients With Systemic Lupus Erythematosus","volume":"40","author":"Daha","year":"1980","journal-title":"Immunology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2012.09.007","article-title":"Autoantibody Stabilization of the Classical Pathway C3 Convertase Leading to C3 Deficiency and Neisserial Sepsis: C4 Nephritic Factor Revisited","volume":"145","author":"Miller","year":"2012","journal-title":"Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00612","article-title":"Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases","volume":"9","author":"Michels","year":"2018","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01350","article-title":"Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy","volume":"10","author":"Michels","year":"2019","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0406-y","article-title":"The Complement Component C5 Is Not Responsible for the Alternative Pathway Activity in Rabbit Erythrocyte Hemolytic Assays During Eculizumab Treatment","volume":"17","author":"van den Heuvel","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e47245","DOI":"10.1371\/journal.pone.0047245","article-title":"Functional Analyses of Complement Convertases Using C3 and C5-Depleted Sera","volume":"7","author":"Okroj","year":"2012","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-1-0716-1016-9_8","article-title":"Functional Hemolytic Test for Complement Alternative Pathway Convertase Activity","volume":"2227","author":"Michels","year":"2021","journal-title":"Methods Mol Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2015.05.018","article-title":"Sensitive, Reliable and Easy-Performed Laboratory Monitoring of Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome","volume":"160","author":"Volokhina","year":"2015","journal-title":"Clin Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2013.05.221","article-title":"An International Serum Standard for Application in Assays to Detect Human Complement Activation Products","volume":"56","author":"Bergseth","year":"2013","journal-title":"Mol Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00467-016-3496-0","article-title":"Serological and Genetic Complement Alterations in Infection-Induced and Complement-Mediated Hemolytic Uremic Syndrome","volume":"32","author":"Westra","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016030343","article-title":"Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative Gn","volume":"28","author":"Marinozzi","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-016-0290-5","article-title":"Testing the Activity of Complement Convertases in Serum\/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis","volume":"36","author":"Blom","year":"2016","journal-title":"J Clin Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.jaci.2020.02.014","article-title":"Gain-Of-Function Mutation in Complement C2 Protein Identified in a Patient With aHUS","volume":"146","author":"Urban","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2012.02.329","article-title":"Acute Presentation and Persistent Glomerulonephritis Following Streptococcal Infection in a Patient With Heterozygous Complement Factor H-Related Protein 5 Deficiency","volume":"60","author":"Vernon","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2014.07.021","article-title":"Heterogeneous Histologic and Clinical Evolution in 3 Cases of Dense Deposit Disease With Long-Term Follow-Up","volume":"45","author":"Figu\u00e8res","year":"2014","journal-title":"Hum Pathol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy050","article-title":"Panel Sequencing Distinguishes Monogenic Forms of Nephritis From Nephrosis in Children","volume":"34","author":"Schapiro","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"B39","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.125.5.2051","article-title":"Relative Resistance of the F-42-Stabilized Classical Pathway C3 Convertase to Inactivation by C4-Binding Protein","volume":"125","author":"Daha","year":"1980","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830141209","article-title":"Protection of the Classical and Alternative Complement Pathway C3 Convertases, Stabilized by Nephritic Factors, From Decay by the Human C3b Receptor","volume":"14","author":"Fischer","year":"1984","journal-title":"Eur J Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.154.1.1","article-title":"Mechanism of Action of the C4 Nephritic Factor. Deregulation of the Classical Pathway of C3 Convertase","volume":"154","author":"Gigli","year":"1981","journal-title":"J Exp Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-015-3311-3","article-title":"C3 Glomerulopathy and Post-Infectious Glomerulonephritis Define a Disease Spectrum","volume":"31","author":"Al-Ghaithi","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.384","article-title":"Atypical Postinfectious Glomerulonephritis is Associated With Abnormalities in the Alternative Pathway of Complement","volume":"83","author":"Sethi","year":"2013","journal-title":"Kidney Int"},{"key":"B44","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrneph.2017.156","article-title":"The Renaissance of Complement Therapeutics","volume":"14","author":"Ricklin","year":"2018","journal-title":"Nat Rev Nephrol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.715704\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T03:31:08Z","timestamp":1673062268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.715704\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,11]]},"references-count":44,"alternative-id":["10.3389\/fimmu.2021.715704"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.715704","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,11]]},"article-number":"715704"}}